Summary of Key Points Core Viewpoint - The article discusses various companies and their shareholders' intentions to buy or sell shares, indicating a trend of both increasing and decreasing shareholdings among different firms in the market [1]. Company Actions - 康缘药业's actual controller's concerted action party increased holdings by 80,000 shares [1]. - 好当家's controlling shareholder plans to reduce holdings by no more than 2.7% [1]. - 亨迪药业's shareholders, including 宁康企管, 倍康企管, and 雷小艳, intend to collectively reduce holdings by no more than 2.33% [1]. - 合兴包装's controlling shareholder 新疆兴汇聚 plans to reduce holdings by no more than 1.91% [1]. - 瑞迈特's shareholder 陈蓓 intends to reduce holdings by no more than 1.76% [1]. - 泰祥股份's 众远投资 plans to reduce holdings by no more than 1% [1]. - 香农芯创's 无锡高新区新动能产业发展基金 reduced holdings by 549,200 shares [1]. - 中国联通's structural adjustment fund will reduce holdings by 40,700,300 shares from November 10 to November 12 [1]. - 方正电机's shareholder 张敏 reduced holdings by 1,632,400 shares [1]. - 畅联股份's directors 徐峰 and 陈文晔 plan to reduce holdings by 0.57% and 0.20%, respectively [1]. - 中兰环保's shareholders 王广庆, 曹丽, and 李泉 plan to reduce holdings by 0.0375%, 0.2798%, and 0.0275%, respectively [1]. - 聚胶股份's director 沃金业 plans to reduce holdings by 0.01% [1]. - 浙江众成's executives 黄旭生 and 潘德祥 plan to reduce holdings by 0.0140% [1]. - 东方中科's shareholder 王戈 plans to reduce holdings by 0.51% [1]. - 海南瑞泽's vice president 于清池 plans to reduce holdings by no more than 0.02% [1].

Core Viewpoint - Changlian Co., Ltd. (603648.SH) announced plans for share reduction by key executives, indicating potential changes in insider ownership and market sentiment [1] Group 1: Executive Share Reduction Plans - The company's General Manager, Mr. Xu Feng, plans to reduce his holdings by up to 2.0652 million shares, representing 0.57% of the total share capital [1] - The company's Deputy General Manager, Ms. Chen Wenye, intends to reduce her holdings by up to 736,400 shares, accounting for 0.20% of the total share capital [1] - Both reductions will occur through centralized bidding on the Shanghai Stock Exchange within a specified period from December 4, 2025, to March 3, 2026 [1]

Group 1 - The company Changlian Co., Ltd. (603648.SH) announced plans for share reduction by its executives [1] - The company's General Manager, Xu Feng, intends to reduce his holdings by up to 2.0652 million shares, representing 0.57% of the total share capital [1] - The company's Deputy General Manager, Chen Wenye, plans to reduce her holdings by up to 736,400 shares, accounting for 0.20% of the total share capital [1]

1 证券代码：603648 证券简称：畅联股份 公告编号：2025-028 上海畅联国际物流股份有限公司 部分董事、高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事、高级管理人员持股的基本情况 截至本减持计划披露日，上海畅联国际物流股份有限公司（以下简称 "公司"）董事、总经理徐峰先生持有公司股份 4,720,362 股，约占公 司总股本的 1.30%；公司董事、副总经理陈文晔女士持有公司股份 1,683,230 股，约占公司总股本的 0.46%。上述股份全部为公司首次公 开发行股票前已持有的股份，该部分股份已于 2018 年 9 月 13 日解除 限售并上市流通。 减持计划的主要内容 自本公告发布之日起十五个交易日后的三个月内，即 2025 年 12 月 4 日至 2026 年 3 月 3 日，公司董事、总经理徐峰先生计划通过上海证券 交易所交易系统集中竞价交易方式进行减持，拟减持不超过 2,065,158 股公司股份,占公司总股本的 0.57%；公司董事、副总经理 ...

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - The investment agreement was signed on November 12, 2025, with Changlian Co. contributing 30 million yuan, which represents 60% of the new company's registered capital [1] - Shanghai Waigaoqiao Biopharmaceutical will contribute 20 million yuan, accounting for 40% of the registered capital [1] - Both parties will collectively hold 100% of the new company's registered capital [1]

证券代码：603648 证券简称：畅联股份 公告编号：2025-027 上海畅联国际物流股份有限公司 二、本次对外投资进展情况 2025 年 11 月，公司与生物医药公司正式签署《出资协议》，主要内容如下： （一）出资协议签署主体 关于对外投资暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | 上海畅联百福医药有限公司 | | --- | --- | | 投资金额（万元） | 3,000 万元 | | 投资进展情况 | 正式签署协议 | | 特别风险提示（如有） | 无 | 一、对外投资基本情况 经上海畅联国际物流股份有限公司（以下简称"公司"或"畅联股份"） 第四届董事会第十二次会议、第四届监事会第十次会议、第四届董事会审计委 员会第十三次会议、第四届董事会独立董事专门会议第四次会议审议通过，同 意公司与上海外高桥生物医药产业发展有限公司（以下简称"生物医药公司"） 合资新设上海畅联百福医药有限公司（以下简称"畅联百福"或"新公司"）， 具 体 内 容 详 见 公 司 ...

Core Viewpoint - The company Changlian Co., Ltd. (stock code: 603648) announced that its general manager Xu Feng and deputy general manager Chen Wenye plan to reduce their shareholdings through centralized bidding transactions, indicating a potential shift in insider ownership and possible implications for investor sentiment [1] Summary by Categories Shareholding Reduction - Xu Feng, the general manager, intends to reduce his holdings by up to 2.0652 million shares, which represents 0.57% of the company's total share capital [1] - Chen Wenye, the deputy general manager, plans to reduce his holdings by up to 736,400 shares, accounting for 0.20% of the company's total share capital [1] Timeline and Pricing - The reduction plan is set to be implemented between December 4, 2025, and March 3, 2026 [1] - The selling price will be determined based on market conditions at the time of the transaction [1] Reason for Reduction - The stated reason for the shareholding reduction is personal financial needs [1] Source of Shares - The shares to be reduced are from those held prior to the company's initial public offering and have already been released from restrictions [1]

格隆汇11月12日丨畅联股份(603648.SH)公布,自本公告发布之日起十五个交易日后的三个月内，即2025 年12月4日至2026年3月3日，公司董事、总经理徐峰先生计划通过上海证券交易所交易系统集中竞价交 易方式进行减持，拟减持不超过206.52万股公司股份,占公司总股本的0.57%；公司董事、副总经理陈文 晔女士计划通过上海证券交易所交易系统集中竞价交易方式进行减持，拟减持不超过73.64万股公司股 份,占公司总股本的0.20%。减持价格视市场价格确定。 ...

Summary of Key Points Core Viewpoint - Changlian Co., Ltd. (603648.SH) announced plans for share reduction by its executives, indicating potential changes in insider ownership and market sentiment [1] Group 1: Share Reduction Plans - The company's General Manager, Mr. Xu Feng, plans to reduce his holdings by up to 2.0652 million shares, representing 0.57% of the total share capital [1] - The company's Deputy General Manager, Ms. Chen Wenye, intends to reduce her holdings by up to 736,400 shares, accounting for 0.20% of the total share capital [1] - The share reduction will be executed through centralized bidding on the Shanghai Stock Exchange, with the selling price determined by market conditions [1]

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - The investment agreement was signed on November 12, 2025, and the new company will be established with a registered capital structure where Changlian Co. will contribute 30 million yuan, representing 60% of the total capital [1] - Shanghai Waigaoqiao Biopharmaceutical will contribute 20 million yuan, accounting for 40% of the registered capital [1] - Both parties will collectively hold 100% of the new company's registered capital [1]